Quince Therapeutics, Inc. Total Assets
Quince Therapeutics, Inc. total assets. Based on the latest financial reports, Quince Therapeutics, Inc. (QNCX) holds total assets worth $124.00 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see QNCX market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Quince Therapeutics, Inc. (2017–2025)
Total assets of Quince Therapeutics, Inc. from 2017 to 2025. This chart illustrates how Quince Therapeutics, Inc.'s total assets have evolved over time, based on quarterly financial data. See current stock price of Quince Therapeutics, Inc. for real-time trading data and today's change.
Quince Therapeutics, Inc. - Asset Composition Analysis
Quince Therapeutics, Inc. Total Assets Breakdown (December 2025)
Quince Therapeutics, Inc. total assets breakdown as of December 2025. Quince Therapeutics, Inc.'s total assets of $124.00 Million consist of 24.5% current assets and 75.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 6.2% |
| Accounts Receivable | $3.62 Million | 3.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $67.82 Million | 72.5% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Quince Therapeutics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore QNCX net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Quince Therapeutics, Inc.'s current assets represent 24.5% of total assets in 2025, a decrease from 97.7% in 2017.
- Cash Position: Cash and equivalents constituted 6.2% of total assets in 2025, down from 95.1% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 72.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is intangible assets at 72.5% of total assets.
Quince Therapeutics, Inc. Competitors by Total Assets
Key competitors of Quince Therapeutics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Quince Therapeutics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.52 | 5.00 | 8.44 |
| Quick Ratio | 14.52 | 5.00 | 8.44 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $114.91 Million | $29.88 Million | $105.27 Million |
Quince Therapeutics, Inc. - Advanced Valuation Insights
This section examines the relationship between Quince Therapeutics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.21 |
| Latest Market Cap to Assets Ratio | 0.33 |
| Asset Growth Rate (YoY) | -18.3% |
| Total Assets | $93.52 Million |
| Market Capitalization | $30.87 Million USD |
Valuation Analysis
Below Book Valuation: The market values Quince Therapeutics, Inc.'s assets below their book value (0.33x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Quince Therapeutics, Inc.'s assets decreased by 18.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Quince Therapeutics, Inc. (2017–2025)
The table below shows the annual total assets of Quince Therapeutics, Inc. from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $93.52 Million | -18.30% |
| 2024-12-31 | $114.48 Million | -36.47% |
| 2023-12-31 | $180.20 Million | +73.42% |
| 2022-12-31 | $103.91 Million | -22.01% |
| 2021-12-31 | $133.23 Million | -29.68% |
| 2020-12-31 | $189.47 Million | +52.34% |
| 2019-12-31 | $124.37 Million | +70.66% |
| 2018-12-31 | $72.88 Million | +844.26% |
| 2017-12-31 | $7.72 Million | -- |
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disord… Read more